Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia

被引：20

作者：

Cuker, Adam ^{[1
]}

Chiang, Elaine Y. ^{[1
]}

Cines, Douglas B. ^{[1
,2
]}

机构：

[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

来源：

CURRENT DRUG SAFETY | 2010年 / 5卷 / 02期

关键词：

ITP; thrombopoiesis; romiplostim; eltrombopag;

D O I：

10.2174/157488610790936196

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The thrombopoiesis-stimulating agents (TSAs) are a novel class of drugs for the treatment of chronic immune thrombocytopenia (ITP). Roimplostim and eltrombopag, the first two TSAs to enter clinical use, received regulatory approval in 2008 and stand poised to change the treatment paradigm in ITP. However, important questions regarding the safety of these agents, particularly with long-term use, remain partially unanswered. The primary objective of this article is to review the reported toxicities associated with the TSAs including rebound thrombocytopenia, thrombosis, hepatotoxicity, formation of neutralizing antibodies, bone marrow fibrosis, hematologic malignancy, cataract formation, and common adverse events. The incidence and severity of these toxicities as well as strategies for monitoring patient safety and pharmacovigilance are discussed.

引用

收藏

页码：171 / 181

页数：11

相关论文

共 75 条

[41] TRANSFORMING GROWTH FACTOR-BETA REGULATES GROWTH AS WELL AS COLLAGEN AND FIBRONECTIN SYNTHESIS OF HUMAN MARROW FIBROBLASTS [J].

KIMURA, A ;

KATOH, O ;

HYODO, H ;

KURAMOTO, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (04) :486-491

[42]

Kline Glaxo Smith, 2008, EM20080000700

[43] Circulating thrombopoietin level in chronic immune thrombocytopenic purpura [J].

Kosugi, S ;

Kurata, Y ;

Tomiyama, Y ;

Tahara, T ;

Kato, T ;

Tadokoro, S ;

Shiraga, M ;

Honda, S ;

Kanakura, Y ;

Matsuzawa, Y .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (03) :704-706

[44]

Kuter D J, 1996, Stem Cells, V14 Suppl 1, P88

[45] Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial [J].

Kuter, David J. ;

Bussel, James B. ;

Lyons, Roger M. ;

Pullarkat, Vinod ;

Gernsheimer, Terry B. ;

Senecal, Francis M. ;

Aledort, Louis M. ;

George, James N. ;

Kessler, Craig M. ;

Sanz, Miguel A. ;

Liebman, Howard A. ;

Slovick, Frank T. ;

de Wolf, J. Th M. ;

Bourgeois, Emmanuelle ;

Guthrie, Troy H., Jr. ;

Newland, Adrian ;

Wasser, Jeffrey S. ;

Hamburg, Solomon I. ;

Grande, Carlos ;

Lefrere, Francois ;

Lichtin, Alan Eli ;

Tarantino, Michael D. ;

Terebelo, Howard R. ;

Viallard, Jean-Francois ;

Cuevas, Francis J. ;

Go, Ronald S. ;

Henry, David H. ;

Redner, Robert L. ;

Rice, Lawrence ;

Schipperus, Martin R. ;

Guo, D. Matthew ;

Nichol, Janet L. .

LANCET, 2008, 371 (9610) :395-403

[46] New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura [J].

Kuter, David J. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 :9-18

[47] Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres [J].

Kuter, David J. ;

Bain, Barbara ;

Mufti, Ghulam ;

Bagg, Adam ;

Hasserjian, Robert P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) :351-362

[48] New thrombopoietic growth factors [J].

Kuter, David J. .

BLOOD, 2007, 109 (11) :4607-4616

[49] Thrombopoietin therapy increases platelet yields in healthy platelet donors [J].

Kuter, DJ ;

Goodnough, LT ;

Romo, J ;

DiPersio, J ;

Peterson, R ;

Tomita, D ;

Sheridan, W ;

McCullough, J .

BLOOD, 2001, 98 (05) :1339-1345

[50] THE PURIFICATION OF MEGAPOIETIN - A PHYSIOLOGICAL REGULATOR OF MEGAKARYOCYTE GROWTH AND PLATELET PRODUCTION [J].

KUTER, DJ ;

BEELER, DL ;

ROSENBERG, RD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) :11104-11108

← 1 2 3 4 5 6 7 8 →